retatrutide trial results news today Lilly's triple agonist achieves 16.8% weight loss in phase 3 First Retatrutide phase 3 data,

doi:10.1016/S0031-9384(04)00348-8 82

44% of them have felt an increased sense of travel freedom

Buyer Takeaway: Budget for the follow-up month price, not the initial month price, when planning ongoing costs

The typical GLP-1 journey involves gradual dose escalation over several months to minimize gastrointestinal side effects while achieving therapeutic benefit

In subgroup analyses based on the drugs used in the control arms, the overall cancer risks were identical in the tirzepatide group compared to the placebo, insulin, and GLP-1RA groups

DHA and EPA, in particular, improve GLP-1 sensitivity in the gut-brain axis, especially when combined with a high-fiber diet